Correlation analysis of measurement result between accelerator mass spectrometry and gamma counter

Minamimoto, Ryogo; Hamabe, Y.; Chen, Cheng; Shimoda, Marika; Oka, Takashi; Inoue, Tomio

doi:10.1007/s12149-009-0327-4

Cited by 2 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In one recent study, an excellent correlation between AMS analysis and biodistribution measurements, using gamma counter, has been demonstrated for [ 14 C]FDG and [ 18 F]FDG, respectively, in various mouse organs, with particularly high correlation between AMS and gamma counter data in brain and plasma [62]. In this in vivo study, a combined iv dose of [ 14 C]FDG and [ 18 F]FDG was administered to mice, and blood and tissue sampling for AMS analysis and analysis by gamma counting was performed at 30 min, 1 h, 2 h and 4 h after administration in different animals.…”

Section: Combination Of Different Analytical Modalities In Microdomentioning

confidence: 99%

Approaches using molecular imaging technology — use of PET in clinical microdose studies

Wagner

Langer

2011

Advanced Drug Delivery Reviews

102

View full text Add to dashboard Cite

Positron emission tomography (PET) imaging uses minute amounts of radiolabeled drug tracers and thereby meets the criteria for clinical microdose studies. The advantage of PET, when compared to other analytical methods used in microdose studies, is that the pharmacokinetics (PK) of a drug can be determined in the tissue targeted for drug treatment. PET microdosing already offers interesting applications in clinical oncology and in the development of central nervous system pharmaceuticals and is extending its range of application to many other fields of pharmaceutical medicine. Although requirements for preclinical safety testing for microdose studies have been cut down by regulatory authorities, radiopharmaceuticals increasingly need to be produced under good manufacturing practice (GMP) conditions, which increases the costs of PET microdosing studies. Further challenges in PET microdosing include combining PET with other ultrasensitive analytical methods, such as accelerator mass spectrometry (AMS), to gain plasma PK data of drugs, beyond the short PET examination periods. Finally, conducting clinical PET studies with radiolabeled drugs both at micro-and therapeutic doses is encouraged to answer the question of dose linearity in clinical microdosing.

show abstract

Section: Combination Of Different Analytical Modalities In Microdomentioning

confidence: 99%

Approaches using molecular imaging technology — use of PET in clinical microdose studies

Wagner

Langer

2011

Advanced Drug Delivery Reviews

102

View full text Add to dashboard Cite

show abstract

Current literature in mass spectrometry

2010

J. Mass Spectrom.

View full text Add to dashboard Cite

Correlation analysis of measurement result between accelerator mass spectrometry and gamma counter

Abstract: Accelerator mass spectrometry analysis has an excellent correlation with biodistribution measurements using gamma counter. Our results suggest that the combination of AMS and PET can act as a complementary approach to accelerate drug development.

Cited by 2 publications

References 22 publications

Approaches using molecular imaging technology — use of PET in clinical microdose studies

Approaches using molecular imaging technology — use of PET in clinical microdose studies

Current literature in mass spectrometry

Contact Info

Product

Resources

About